India, Oct. 3 -- AstraZeneca Pharma India has received approval from theCentral Drugs Standard Control Organisation (CDSCO)to import, market, and distributeTrastuzumab Deruxtecan (100mg/5mL vial lyophilised powder for concentrate for solution for infusion)for an additional indication in India.

With this approval,Trastuzumab Deruxtecanis now indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumours who have received prior systemic therapy and have no satisfactory alternative treatment options. This marks the first and only antibody drug conjugate (ADC) in India with a tumour-agnostic indication, representing a significant advancement in precision oncology.

HER2 overexpression, which...